Kyntra Bio (NASDAQ:KYNB – Get Free Report) was upgraded by Lake Street Capital to a “strong-buy” rating in a report issued on Thursday, Zacks reports.
KYNB has been the subject of a number of other research reports. Oppenheimer initiated coverage on shares of Kyntra Bio in a research report on Monday, July 6th. They set an “outperform” rating and a $35.00 price objective for the company. Rodman & Renshaw started coverage on Kyntra Bio in a research report on Tuesday, June 9th. They set a “buy” rating and a $30.00 price objective on the stock. Weiss Ratings raised shares of Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $43.00 target price on shares of Kyntra Bio in a research report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kyntra Bio presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.
Kyntra Bio Price Performance
Institutional Investors Weigh In On Kyntra Bio
An institutional investor recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC purchased a new stake in Kyntra Bio Inc (NASDAQ:KYNB – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned 0.68% of Kyntra Bio at the end of the most recent reporting period. Institutional investors own 72.71% of the company’s stock.
About Kyntra Bio
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Further Reading
- Five stocks we like better than Kyntra Bio
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
